Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020

/PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020...

Related Keywords

Taiwan ,Canada ,Australia ,Taipei ,T Ai Pei ,Wenjin Yang ,Ben Chien ,Pharmaceuticals Co Ltd ,Prnewswire Foresee Pharmaceuticals Tpex ,Taipei Exchange Tpex ,Chief Scientific ,Taipei Exchange ,Stabilized Injectable Formulation ,Fuschia Phase ,Foresee Pharmaceuticals Co ,Td ,